Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04043195 2025-05-28

NSCLC

Phase 1/2 Active not recruiting

30 enrolled

Thoracic

Advanced NSCLC

NCT06926790 2025-04-22

GALAXY 3

Phase 2 Recruiting

69 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03262779 2025-01-09

Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.

Phase 2 Completed

20 enrolled 16 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03043599 2024-12-20

Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

Phase 1/2 Completed

21 enrolled 11 charts

Thoracic

Small Cell Lung Carcinoma

NCT05501665 2024-10-17

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Phase 1/2 Recruiting

25 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06492421 2024-07-09

Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.

Phase 2 Recruiting

90 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04610658 2024-04-02

Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

Phase 1 Terminated

9 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04300244 2024-02-29

NIPU

Phase 2 Active not recruiting

118 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Lung Neoplasms, Mesothelioma, Neoplasms

NCT03083691 2024-01-17

BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer

Phase 2 Completed

90 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT05041062 2024-01-03

A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma

Phase 2 Completed

2 enrolled 8 charts

Other solid neoplasmThoracic

Lung Neoplasms, Mesothelioma

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

400 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT03509584 2023-06-15

Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients

Phase 1 Terminated

6 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03168464 2023-04-24

Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)

Phase 1/2 Terminated

15 enrolled 9 charts

Thoracic

Non Small Cell Lung Cancer Metastatic

NCT03406715 2023-03-30

Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)

Phase 2 Terminated

14 enrolled 12 charts

Thoracic

Lung Diseases, Lung Neoplasms, Small Cell Lung Carcinoma

NCT03351361 2023-03-01

eNERGY

Phase 3 Completed

217 enrolled

Thoracic

Advanced Non Small Cell Lung Cancer

NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

Unknown

1,800 enrolled

DermatologicGenitourinaryThoracic

Kidney Neoplasms, Lung Neoplasms, Melanoma

NCT03663166 2023-02-15

Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Terminated

19 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05597800 2022-10-28

LUNGVIR

Phase 2 Not yet recruiting

105 enrolled

Thoracic

Post-Acute COVID-19 Syndrome, Carcinoma, Non-Small-Cell Lung

NCT04571632 2022-09-14

Luscid

Phase 2 Unknown

36 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04434560 2022-07-26

Neoadjuvant Immunotherapy in Brain Metastases

Phase 2 Terminated

1 enrolled 7 charts

BreastCNSDermatologicGenitourinaryGynecologicThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

FLINN

REVIVE

Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer

Osi+Ipi

ALCG-01

NIVIPI-Brain

TOP2101

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab

KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC

Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

RAD-IO

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer

COSINR

G360-IIT

DREAM3R

Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

ATLAS

NA_00092076

DICIPLE

TOP1705

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

NSCLC

GALAXY 3

Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.

Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.

Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

NIPU

BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer

A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma

ROME

Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients

Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)

Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)

eNERGY

Microbiome Immunotherapy Toxicity and Response Evaluation

Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)

LUNGVIR

Luscid

Neoadjuvant Immunotherapy in Brain Metastases